Affiliation:
1. Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Excellence Specialties “G. D’Alessandro”, University of Palermo, 90127 Palermo, Italy
2. Sicilian Reference Laboratory for Integrated Surveillance of Respiratory Viruses, University Hospital of Palermo, 90127 Palermo, Italy
Abstract
The current influenza season started in Italy in October 2023, approaching the epidemic peak in late December (52nd week of the year). We aimed to explore the mid-term virologic surveillance data of the 2023/2024 influenza season (from 16 October 2023 to 7 January 2024) in Sicily, the fourth most populous Italian region. A test-negative design was used to estimate the effectiveness of seasonal influenza vaccine (VE) against A(H1N1)pdm09 virus, the predominant subtype in Sicily (96.2% of laboratory-confirmed influenza cases). Overall, 29.2% (n = 359/1230) of oropharyngeal swabs collected from patients with influenza-like illness (ILI) were positive for influenza. Among the laboratory-confirmed influenza cases, 12.5% (n = 45/359) were vaccinated against influenza, with higher prevalence of laboratory-confirmed diagnosis of influenza A among subjects vaccinated with quadrivalent inactivated standard dose (29.4%), live attenuated intranasal (25.1%), and quadrivalent inactivated high-dose (23.8%) influenza vaccines. Comparing influenza vaccination status for the 2023/2024 season among laboratory-confirmed influenza-positive and -negative samples, higher vaccination rates in influenza-negative samples (vs. positive) were observed in all age groups, except for 45–64 years old, regardless of sex and comorbidities. The overall adjusted VE (adj-VE) was 41.4% [95%CI: 10.5–61.6%], whereas the adj-VE was 37.9% [95%CI: −0.7–61.7%] among children 7 months–14 years old and 52.7% [95%CI: −38.0–83.8%] among the elderly (≥65 years old).
Reference25 articles.
1. World Health Organization (2024, January 25). Influenza Surveillance Reports. Available online: https://www.who.int/teams/global-influenza-programme/surveillance-and-monitoring/influenza-surveillance-outputs.
2. Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season;Smolarchuk;Eurosurveillance,2024
3. A mid-term estimate of 2018/2019 vaccine effectiveness to prevent laboratory confirmed A(H1N1)pdm09 and A(H3N2) influenza cases in Sicily (Italy);Costantino;Vaccine,2019
4. Interim 2022/23 influenza vaccine effectiveness: Six European studies, October 2022 to January 2023;Kissling;Eurosurveillance,2023
5. World Health Organization (2024, January 25). Recommended Composition of Influenza Virus Vaccines for Use in the 2023–2024 Northern Hemisphere Influenza Season. Available online: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2023-2024-northern-hemisphere-influenza-season.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献